Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(1)
•••
Post by skyhigh123on Mar 08, 2018 10:51pm
167 Views
Post# 27688662

Prometic’s Patents World Wide

Prometic’s Patents World Wide

60 results found in the Worldwide database for:

ia = Prometic using Smart search

 
Results are sorted by date of upload in database
 
 1.  COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
 

Publication info:

 KR20180011332 (A) 2018-01-31
 2.  SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
 

Publication info:

 KR20180010332 (A) 2018-01-30
 3.  MEDIUM-CHAIN LENGTH FATTY ACIDS AND GLYCERIDES AS NEPHROPROTECTION AGENTS
 

Publication info:

 ZA201003030 (B) 2011-02-23
 4.  PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARMACEUTICAL USES THEREOF
 

Publication info:

 MY164375 (A) 2017-12-15
 5.  PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS.
 

Publication info:

 MX2017004735 (A) 2017-11-17
 6.  METHOD FOR THE PREPARATION OF TRIGLYCERIDES OF MEDIUM-CHAIN LENGTH FATTY ACIDS.
 

Publication info:

 ZA201405956 (B) 2016-08-31
 7.  SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS
 

Publication info:

 ZA201507062 (B) 2017-04-26
 8.  SUBSTITUTED AROMATIC COMPOUNDS AND RELATED METHOD FOR THE TREATMENT OF FIBROSIS
 

Publication info:

 ZA201507061 (B) 2017-03-26
 9.  PHARMACEUTICAL COMPOSITION COMPRISING PLASMINOGEN AND USES THEREOF
 

Publication info:

 US2017360902 (A1) 2017-12-21
 10.  SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETES
 

Publication info:

 PH12017500662 (A1) 2017-10-02
 11.  SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS
 

Publication info:

 PH12017500638 (A1) 2017-09-25
 12.  SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION
 

Publication info:

 PH12017500856 (A1) 2017-11-06
 13.  Plasminogen replacement therapy for plasminogen-deficiency
 

Publication info:

 TW201722463 (A) 2017-07-01
 14.  Plasminogen dosage regimen for wound healing
 

Publication info:

 TW201722464 (A) 2017-07-01
 15.  MEDIUM -CHAIN LENGTH FATTY ALCOHOLS AS STIMULATORS OF HEMATOPOIESIS
 

Publication info:

 TNSN07112 (A1) 2008-06-02
 16.  SUBSTITUTED TRIAZINES AS PRION PROTEIN LIGANDS AND THEIR USE TO DETECT OR REMOVE PRIONS
 

Publication info:

 TNSN07019 (A1) 2008-06-02
 17.  SUBSTITUTED PURINYL DERIVATIVES WITH IMMUNOMODULATOR AND CHEMOPROTECTIVE ACTIVITY AND USE ALONE OR WITH MEDIUM - CHAIN LENGTH FATTY ACIDS OR GLYCERIDES
 

Publication info:

 TNSN07068 (A1) 2008-06-02
 18.  MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS STIMULATORS OF ERYTHROPOIESIS
 

Publication info:

 TNSN05189 (A1) 2007-06-11
 19.  PREPARATION OF METAL SALTS OF MEDIUM-CHAIN FATTY ACIDS
 

Publication info:

 TNSN06028 (A1) 2007-10-03
 20.  AFFINITY ADSOBENTS FOR FIBRINOGEN
 

Publication info:

 PT1885487 (E) 2016-06-02
 21.  AFFINITY ADSORBENTS FOR PLASMINOGEN
 

Publication info:

 PT1885485 (E) 2016-06-02
 22.  AFFINITY ADSORBENTS FOR FACTOR VIII AND VON WILLEBRAND'S FACTOR
 

Publication info:

 PT1885486 (E) 2016-06-02
 23.  SALTS OF 3-PENTYLPHENYLACETIC ACID AND PHARMACEUTICAL USES THEREOF
 

Publication info:

 BRPI1015118 (A2) 2016-04-12
 24.  MEDIUM-CHAIN LENGTH FATTY ACIDS, SALTS AND TRIGLYCERIDES IN COMBINATION WITH GEMCITABINE FOR TREATMENT OF PANCREATIC CANCER
 

Publication info:

 BRPI0821395 (A2) 2015-06-16
 25.  MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS
 

Publication info:

 JP2014231519 (A) 2014-12-11
 26.  METHOD FOR TREATMENT OF INFLAMMATION
 

Publication info:

 TNSN03022 (A1) 2005-12-23
 27.  TRIAZINE DIMERS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
 

Publication info:

 PT1687297 (E) 2014-09-18
 28.  "TRIAZINE DERIVATIVES, COMPOSITIONS CONTAINING SUCH DERIVATIVES, AND METHODS OF TREATMENT OF CANCER AND AUTOIMMUNE DISEASES USING SUCH DERIVATIVES"
 

Publication info:

 BRPI0810921 (A2) 2014-10-29
 29.  SUBSTITUTED TRIAZINES AS PRION PROTEIN LIGANDS AND THEIR USE TO DETECT OR REMOVE PRIONS
 

Publication info:

 HK1110314 (A1) 2014-07-18
 30.  Endotoxin-binding ligands and their use
 

Publication info:

 US2005238641 (A1) 2005-10-27
 31.  SEQUENTIAL PROTEIN ISOLATION AND PURIFICATION SCHEMES BY AFFINITY CHROMATOGRAPHY.
 

Publication info:

 MY147996 (A) 2013-02-28
 32.  ADSORBENTS FOR PROTEIN PURIFICATION
 

Publication info:

 ES2430556 (T3) 2013-11-21
 33.  Method of detecting infectious prion protein having hydrophilic, hydrophobic or amphiphilic functional group
 

Publication info:

 IL171279 (A) 2014-01-30
 34.  Compounds and Pharmaceutical Compositions for Uses in Diabetes
 

Publication info:

 US2013225683 (A1) 2013-08-29
 35.  Triaziner som proteinbindingsligander
 

Publication info:

 DK1899308 (T3) 2013-02-11
 36.  TRIAZINE BASED LIGANDS AND USE THEREOF
 

Publication info:

 MY127957 (A) 2007-01-31
 37.  Method for purifying albumin
 

Publication info:

 CN102549012 (A) 2012-07-04
 38.  TRIAZINE COMPOUNDS AND THEIR USE IN FORMING MULTIDIMENSIONAL LIBRARIES FOR AFFINITY CHROMATOGRAPHY
 

Publication info:

 DK1569918 (T3) 2011-11-28
 39.  Triazine compounds and compositions thereof for the treatment of cancers
 

Publication info:

 NZ563245 (A) 2011-04-29
 40.  PURINE DERIVATIVES AND THEIR USE FOR TREATMENT OF AUTOIMMUNE DISEASES
 

Publication info:

 BRPI0610824 (A2) 2010-07-27
 41.  COMPOSITION AND METHOD FOR TREATING INFLAMMATORY DISEASES USING PROTEASE INHIBITORS
 

Publication info:

 ES2330516 (T3) 2009-12-11
 42.  SUBSTITUTED PHENYLPROPIONIC ACIDS AS STIMULATORS OF HEMATOPOIESIS AND ERYTHROPOIESIS
 

Publication info:

 WO2009055932 (A1) 2009-05-07
 43.  PROTEIN BINDING LIGANDS
 

Publication info:

 BRPI0611811 (A2) 2008-12-09
 44.  2,4,6-TRIAMINO-S-TRIAZINE-BASED COMPOUNDS WHICH BIND TO THE TAIL (FC) PORTION OF IMMUNOGLOBULINS AND THEIR USE.
 

Publication info:

 MX2007002728 (A) 2008-03-04
 45.  Process for making fluorinated polymer adsorbent particles
 

Publication info:

 US6573307 (B1) 2003-06-03
 46.  Medium-Chain Length Fatty Alcohols as Stimulators of Hematopoiesis
 

Publication info:

 US2008051324 (A1) 2008-02-28
 47.  NOVEL TRIAZINE-BASED DETOXIFICATION AGENTS AND THEIR USE
 

Publication info:

 US2008096220 (A1) 2008-04-24
 48.  Apparatus and method for producing porous polymer particles
 

Publication info:

 US2005006496 (A1) 2005-01-13
 49.  Use of adsorbent polymer particles in DNA separation
 

Publication info:

 US2003162853 (A1) 2003-08-28
 50.  Macrocyclic compounds and their use
 

Publication info:

 US2004115724 (A1) 2004-06-17
 51.  Triazine based ligands and use thereof
 

Publication info:

 US6117996 (A) 2000-09-12
 52.  METHOD FOR THE TREATMENT OF INFLAMMATION.
 

Publication info:

 MXPA03004017 (A) 2004-02-12
 53.  DRY RECOMBINANT HUMAN ALPHA 1-ANTITRYPSIN FORMULATION
 

Publication info:

 WO2005047323 (A1) 2005-05-26
 54.  THE USE OF METAL-CHELATING ADSORBENTS
 

Publication info:

 WO03045546 (A1) 2003-06-05
 55.  STERILE COMPOSITION AND ITS PREPARATION
 

Publication info:

 WO02064117 (A1) 2002-08-22
 56.  METAL-CHELATING ADSORBENTS AND THEIR USE
 

Publication info:

 WO0241989 (A1) 2002-05-30
 57.  PARTICLES AND THEIR USE IN MOLECULAR IMPRINTING
 

Publication info:

 WO0198784 (A2) 2001-12-27
 58.  THE USE OF POLYMER ADSORBENT PARTICLES IN DNA SEPARATION
 

Publication info:

 WO0196556 (A1) 2001-12-20
 59.  MACROCYCLIC COMPOUNDS AND THEIR USE
 

Publication info:

 WO0142228 (A1) 2001-06-14
 60.  APPARATUS AND METHOD FOR PRODUCING POROUS POLYMER PARTICLES
 

Publication info:

 CA2417285 (A1) 2002-02-14
 
 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities